



REVIEW

Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation

[version 1; peer review: 2 approved]

Effie W. Petersdorf

Fred Hutchinson Cancer Research Center, Seattle, WA, USA

V1 First published: 03 May 2017, 6(F1000 Faculty Rev):617
<https://doi.org/10.12688/f1000research.10990.1>

Latest published: 03 May 2017, 6(F1000 Faculty Rev):617
<https://doi.org/10.12688/f1000research.10990.1>

Abstract

Graft-versus-host disease (GVHD) remains a significant potentially life-threatening complication of allogeneic hematopoietic cell transplantation (HCT). Since the discovery of the human leukocyte antigen (HLA) system over 50 years ago, significant advances have clarified the nature of HLA variation between transplant recipients and donors as a chief etiology of GVHD. New information on coding and non-coding gene variation and GVHD risk provides clinicians with options to consider selected mismatched donors when matched donors are not available. These advances have increased the availability of unrelated donors for patients in need of a transplant and have lowered the overall morbidity and mortality of HCT.

Keywords

MHC, hematopoietic cell transplantation, permissible HLA mismatch, haplotype, HLA expression

Open Peer Review

Approval Status

	1	2
version 1 03 May 2017		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Richard Champlin**, University of Texas MD Anderson Cancer Center, Houston, USA
2. **Dietrich Beelen**, Universitätsklinikum Essen, Essen, Germany

Any comments on the article can be found at the end of the article.

Corresponding author: Effie W. Petersdorf (epetersd@fredhutch.org)

Competing interests: The author declares that she has no competing interests.

Grant information: Funding was received from the National Institutes of Health (grant numbers AI069197, CA100019, CA162194, and CA18029).

Copyright: © 2017 Petersdorf EW. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original data is properly cited.

How to cite this article: Petersdorf EW. **Role of major histocompatibility complex variation in graft-versus-host disease after hematopoietic cell transplantation [version 1; peer review: 2 approved]** F1000Research 2017, **6**(F1000 Faculty Rev):617 <https://doi.org/10.12688/f1000research.10990.1>

First published: 03 May 2017, **6**(F1000 Faculty Rev):617 <https://doi.org/10.12688/f1000research.10990.1>

Introduction

Patients with life-threatening malignant and non-malignant blood disorders can be cured through hematopoietic cell transplantation (HCT). Although siblings who share identical parent human leukocyte antigen (HLA) haplotypes remain the preferred donor, the probability that any given patient has a matched sibling donor depends on family size. For patients without HLA-matched siblings, the development of registries of unrelated donors worldwide has greatly facilitated the identification of suitable unrelated donors for transplantation^{1,2}. In the half century since the discovery of the HLA system³⁻⁶, major advances in our understanding of the HLA barrier have made possible the use of donors with selected HLA mismatches and have provided many patients with the opportunity for a life-saving transplant, particularly patients of non-Caucasian ancestry. A complete understanding of the HLA barrier in graft-versus-host disease (GVHD) after unrelated donor HCT requires an appreciation of the unique features of the classical HLA genes, non-HLA loci resident to the human MHC, and the constituents of extended MHC haplotypes. This review describes the current state of the art for transplantation from unrelated donors. Significant advances in the use of HLA-mismatched haploidentical related donors with post-transplantation cyclophosphamide to overcome the effects of HLA mismatching on the non-shared haplotype allow successful transplantation for patients without unrelated donors⁷. The reader is referred to some outstanding comprehensive reviews in the current practice of haploidentical transplantation^{8,9}.

The major histocompatibility complex

The human major histocompatibility complex (MHC) encodes a series of genes on chromosome 6p, of which the best known are the classical class I and class II loci. A formal definition of the MHC was made possible with complete sequencing of a reference haplotype of approximately 3.8 megabases (Mb)¹⁰. Today, over 269 loci are recognized¹¹ and include four major classes of variation: protein coding, non-coding RNAs, small nucleolar RNAs, and pseudogenes. The HLA region is characterized not only by very high gene density but also by extensive sequence variation, particularly of the classical HLA loci. MHC loci are well known for their high degree of association with over 100 diseases¹². Together with the fundamental role of HLA proteins in the transplantation barrier, the MHC region remains one of the best-studied regions of the human genome.

HLA alloantigens were first identified in 1952 by way of complement-dependent microcytotoxicity assays that were informative for anti-HLA antibodies from blood donors and multiparous females³⁻⁶. Serologic methods were the mainstay of tissue typing early in the history of the field but since have been supplanted by molecular methods. Today, next-generation sequencing (NGS) platforms designed to comprehensively characterize large segments of HLA genes and in some cases establish the cis-relationship between markers provide investigators with an unprecedented view of sequence diversity and the organization of variation on haplotypes¹³⁻¹⁶. Use of molecular tools for HLA genes has led to the recognition of over 3,830 HLA-A, 4,647 HLA-B, 3,382 HLA-C, 2,011 HLA-DRB1, 1,054 HLA-DQB1, and 740 HLA-DPB1 alleles, just to name the six classical loci currently

considered in the selection of HCT donors¹⁷. The unique HLA allotypes are distinguished by substitutions at key residues that define the peptide-binding region (PBR) of the molecule. The nature of PBR substitutions reflects the antigen-presentation role of HLA molecules in host defense. In transplantation, the extraordinary degree of variation can present a major roadblock to the identification of donors for transplantation, as described below.

Graft-versus-host disease after unrelated donor hematopoietic cell transplantation: the role for human leukocyte antigen alloantigens

GVHD is the second most prevalent cause of mortality after unrelated donor HCT¹⁸. HLA mismatching remains one of the strongest risk factors for risk of acute and chronic GVHD and therefore upfront efforts to identify matched donors have been the mainstay of pre-transplant donor evaluation^{2,19-21}. The probability of finding HLA-matched donors depends on the race of the patient and on the composition of donor registries²². Although international registries have high representation of donors of European Caucasian ancestry, this does not guarantee that Caucasian patients will always have matched donors. In general, the probability of finding HLA-A, -B, -C, and -DRB1 (HLA “8/8”) mismatched donors is related to the parental alleles and haplotypes and their frequencies in donor registries^{23,24}. An analysis by the National Marrow Donor Program (NMDP) of the Be The Match Registry demonstrated that the rate of matching all 10 alleles at HLA-A, -C, -B, -DRB1, and -DQB1 loci was lower for African-, Hispanic-, and Asian-Americans (<50%) than for Caucasian-Americans²⁵. To estimate the likelihood that a less-than-perfect match could be identified for any given patient, a follow-up analysis by the NMDP focused on the probability of finding HLA 7/8-matched donors (one mismatch at HLA-A, -C, -B, or -DRB1). Compared to Caucasian-Americans with 98% likelihood, Hispanic-, Asian-, and African-American patients had 86%, 88%, and 82% likelihoods, respectively²⁶. When matching considered all five loci, the probability of identifying a donor with a single mismatch (HLA 9/10) was 94%, 72%, 74%, and 61%, respectively. These data suggest that when an HLA 7/8- or 10/10-matched unrelated donor is not available, it is feasible to identify donors with one HLA mismatch.

Substantial data from transplant centers and transplant registries confirm the importance of complete and precise donor HLA matching to lower the risks of GVHD^{2,19,20,27}; however, data concerning the acceptability of limited HLA mismatching when matched donors are not available are still coming into focus. A major impetus for understanding which mismatches can be used safely (i.e. are not associated with significantly increased risk of GVHD) and which mismatches should be avoided is the premise that relaxing donor selection criteria will substantially increase the odds of identifying donors for all patients. In fact, for patients of African-American background, over 80% will have donors mismatched for one HLA-A, -B, -C, or -DRB1 allotype²⁶.

To better understand the genetic basis for patient-donor mismatches that increase GVHD risk (and which should be avoided if possible), investigation has focused on the polymorphic exons that define the PBR of class I and II allotypes. For HLA-A, -B, and -C,

this includes characterization of exons 2, 3, and 4, which encode the $\alpha 1$, $\alpha 2$, and $\alpha 3$ extracellular domains, respectively; whereas the $\alpha 1$ and $\alpha 2$ domains fold to form the PBR between two α helices on a β -pleated sheet platform, the membrane-proximal $\alpha 3$ domain encodes the main binding site for CD8 and contact residues for $\beta 2$ microglobulin^{28,29}. For class II HLA-DR and -DQ allotypes, definition of the transplant recipient and donor includes, at a minimum, the polymorphic exon 2, which encodes the residues that define the PBR.

Qualitative and quantitative factors of human leukocyte antigen disparity in graft-versus-host disease risk

A role for donor-recipient mismatching at the classical HLA-A, -B, -C, -DRB1, and -DQB1 loci in GVHD risk has been amply demonstrated^{2,19,20,27}. Investigation into the clinical significance of the sixth and last classical HLA gene, *HLA-DP*, required additional laboratory tools because traditional typing of *HLA-DP* gene products was performed through a secondary primed lymphocyte reaction which did not distinguish between allelic variants. Through a variety of different approaches, HLA-DP has been confirmed as a classical MHC locus in HCT^{30–33}.

Early clinical experience demonstrated the high-risk nature of additive effects of multi-locus mismatching, which led to the practice of limiting the total number of HLA mismatches between the transplant donor and recipient³⁴. The importance of HLA mismatch dose was further illustrated with the HLA-C locus³⁵. Historically, donor matching included consideration for HLA-A, -B, and -DRB1; when retrospective analysis of HLA-C was feasible with molecular tools, many HLA “6/6”-matched transplants were retrospectively identified to have one or two HLA-C mismatches. The risk of graft failure increased with increasing number of HLA-C mismatches³⁵. Similar synergistic effects have been shown for HLA-DPB1³⁰ and recently for the HLA-DRB1/-DRB3/-DRB4/-DRB5 loci³⁶. Updated analyses by the Japan Marrow Donor Program (JMDP)²⁰ and the Center for International Blood and Marrow Transplant Research (CIBMTR)² both confirm the deleterious nature of multi-locus HLA mismatching on GVHD and mortality. For this reason, limiting the total number of donor HLA mismatches to one will help to lower the risk of GVHD and mortality after HCT²¹.

When matched donors are not available, research suggests that the judicious selection of donors with selected HLA mismatches may provide patients with a curative transplant without substantially increasing transplant-related mortality. These research studies have identified selected HLA mismatch combinations that differ at specific amino acid residues which define the class I PBR^{37,38}. The JMDP experience has identified patient-donor mismatching at four key class I residues as risk factors for acute GVHD: Tyr9Ser, Tyr99Phe, Leu116Ser, and Arg156Leu were each associated with a significantly increased risk of acute GVHD among Japanese patients³⁹. Of these positions, mismatching at residue 116 was associated with increased mortality in a large retrospective analysis by the CIBMTR, providing independent validation of the importance of this epitope⁴⁰. At the HLA-DPB1 locus, *in vitro* cytotoxicity assays have been developed

to evaluate the immunogenicity of amino acid residue mismatching^{41–43}. Patient-donor mismatching for amino acid residues that define the hypervariable regions of DP β is associated with GVHD risk and can be used to define combinations of patient-donor HLA-DPB1 mismatches that are associated with higher risks (“HLA-DPB1 non-permissive mismatches”) and those associated with GVHD rates not dissimilar to those observed among HLA-DPB1-matched transplants (“HLA-DPB1 permissive mismatches”) ^{44,45}. A clinically useful tool for evaluating patient-donor HLA-DPB1 mismatches has been developed with the aid of mutational studies⁴⁶. In an independent study, recipient residues encoded by the DPA1*01:03–DPB1*04:01 haplotype that define the HLA-DP peptide-binding pocket have been shown to correlate with sclerotic GVHD⁴⁷. These studies collectively support the hypothesis that motifs of the HLA-DP PBR are involved in GVH recognition.

Differences between the transplant donor’s and recipient’s HLA molecules at key amino acid residues within the PBR stimulate robust GVH alloresponses. In addition to such qualitative measures of GVH allorecognition are quantitative measures in which donor recognition of patient MHC differences is influenced by the amount of HLA protein expressed by host cells and tissues. Recently, demonstration that the level of expression of HLA-C and HLA-DP allotypes in patients with HIV and hepatitis B infection influence the course of these infections highlights the need for more complete information on the extent and nature of non-coding region variation within the HLA system^{48,49}. Both the HIV-AIDS and hepatitis B models suggest that higher HLA expression promotes more effective presentation of virally associated minor antigens and enhanced host clearing of infection. Alternatively, lower HLA-C expression is protective in Crohn’s disease, suggesting a key role for HLA-C in the presentation of immunogenic antigens that participate in autoimmunity⁴⁸.

In HCT, the level of expression of HLA-C and HLA-DP mismatches in the patient is associated with risks of GVHD and mortality. HLA-C expression is allotype specific and follows a continuous spectrum of mean fluorescence intensity values, with HLA-C*03 and HLA-C*07 expressed at low levels compared to HLA-C*14, which is expressed at very high levels⁴⁸. Among transplants mismatched for one HLA-C antigen, as the level of the patient’s mismatched HLA-C allotype increases, the risk of GVHD increases⁵⁰. HLA-DP expression is influenced by the rs9277534 variant that resides in the gene’s 3’ untranslated region (UTR), where possession of the A allele is associated with low HLA-DP expression and G with high expression⁴⁹. Among transplants mismatched for one HLA-DP antigen, patients with low-expression HLA-DP mismatches had lower risk of GVHD compared to patients with high-expression HLA-DP mismatches⁵¹.

The same loci that increase GVHD risk are also associated with lowered probability of relapse after transplantation. Known as the graft-versus-leukemia effect (GVLE)^{52–55}, mismatching at HLA-C and HLA-DPB1 are most strongly associated with GVLE compared to mismatching at other classical HLA loci²⁰. The potent immunogenicity of HLA-DPB1 has recently been exploited in an *in vitro* model in which CD45RA-selected CD4 cytotoxic

lymphocytes (CTLs) were stimulated with autologous dendritic cells that expressed HLA-DPB1 mismatched alleles on mRNA transfection⁵⁶. AML blasts that expressed the corresponding HLA-DPB1 alleles were directly lysed by the CTLs. These novel data provide a platform for the development of AML-reactive CTLs that use HLA-DPB1 as a potent target to mediate GVL responses.

The role for major histocompatibility complex resident non-human leukocyte antigen loci in graft-versus-host disease

Candidate gene studies

Genetic variation within the MHC is inherited *en bloc* in classical Mendelian fashion as a haplotype of markers on the same chromosomal strand. With current donor-matching criteria, less than 5% of the total MHC resident gene content is evaluated, and this opens up the potential for novel undetected variation as a cause of GVHD after HLA-matched transplantation. Together with HLA alleles, non-HLA loci in the MHC travel together, and their biological effects may synergize with those stemming from donor-recipient HLA mismatches. There has been strong interest in exploring non-HLA loci as a source of variation responsible for GVHD, particularly in the setting of HLA-matched transplantation^{57,58}. Studies have approached the search for novel transplantation determinants through candidate gene approaches or fine mapping with the aid of single nucleotide polymorphisms (SNPs) that define blocks of tightly linked markers (tagSNPs). In the case of unrelated donors and patients, identity for HLA alleles does not guarantee identity for other MHC loci, particularly if the patient's and donor's haplotypes are different⁵⁹.

A growing number of studies have taken a candidate gene approach to explore the clinical significance of the non-classical class I loci including *HLA-E*, *HLA-G*, and MHC class I related chain A (*MICA*). Each of these genes is polymorphic and each has unique features that make them interesting candidates for transplantation determinants. A total of 25 HLA-E alleles that give rise to 18 proteins have been recognized; however, two alleles, E*01:01 and E*01:03, are the most frequently observed in most populations studied thus far¹⁷. Given its participation in both the innate and the adaptive immune pathways, *HLA-E* has been an attractive candidate gene with the potential to influence the risk of GVHD after transplantation; however, the evidence to date is heterogeneous⁶⁰⁻⁶⁴. In HLA-matched sibling transplantation, homozygosity for HLA-E*01:03 was protective for GVHD and associated with improved survival^{60,62}. The presence of E*01:03 in transplant donors, however, was associated with higher grades (II-IV) of acute GVHD⁶¹. Two additional studies did not find an association of HLA-E with clinical outcome^{63,64}.

HLA-G is a non-classical class I gene best studied for its role in tolerance at the maternal-fetal placental interface^{65,66}. *HLA-G* encodes a total of 53 allelic variants giving rise to 18 proteins¹⁷. However, the most intriguing characteristic of this non-classical gene is its ability to form soluble as well as membrane-bound protein as a result of alternative splicing. A total of four membrane-bound and three soluble isoforms differ with respect to their size, structure, and ability to bind $\beta 2$ microglobulin^{67,68}.

The transcriptional regulation of *HLA-G* is complex and includes, but is not limited to, genetic variation within the 5' and the 3' UTRs⁶⁹⁻⁷¹. The 3' UTR is particularly interesting, as it is characterized by a 14 basepair (bp) insertion/deletion and by haplotypes of SNPs, of which rs1063320 has been the subject of intense investigation as a basis for *HLA-G* expression and disease association⁷¹⁻⁷⁴. The 14 bp insertion results in the removal of 92 bases from exon 8 and is correlated with lower expression of *HLA-G* transcript^{75,76}. Its participation in both T and natural killer (NK) cell-mediated immune pathways^{68,77-80} has prompted investigation into a role for *HLA-G* gene products in cancer, autoimmunity, and transplantation^{74,79,81}.

In HCT, homozygosity for the 14 bp deletion correlated with higher risk of acute GVHD compared to homozygosity for the 14 bp insertion⁸². In an independent study, however, the 14 bp insertion was found to be a risk factor for acute GVHD⁸³. No correlation of the 14 bp insertion was found for acute GVHD, but an association with lower overall survival and disease-free survival was observed⁸⁴. Still, other investigations have not found associations among 3' UTR haplotypes, the 14 bp insertion/deletion, and clinical outcome after HCT^{85,86}.

Although it has classically been considered that HLA-G expression is restricted to the maternal-fetal interface, the thymus, and the cornea, several recent studies have found increased levels of HLA-G in the plasma⁸⁷⁻⁸⁹ and in GVHD target organs in patients receiving allogeneic HCTs⁸⁷. In the first 30 days after HCT, levels of the soluble G5, G6 and G7 proteins were significantly higher compared to pre-transplant levels; higher levels of soluble HLA-G proteins were found in patients without GVHD compared to lower levels in patients who developed grades II-IV acute GVHD⁸⁹. Very intriguing data on the recovery of CD14⁺ HLA-G⁺ cells in the plasma of healthy and transplant patients and the ability to antagonize the suppressive function of these cells through HLA-G blockade provide new information on the contribution of HLA-G-expressing monocytes in the immune response⁸⁷. Transplant recipients were found to have a higher frequency of HLA-G⁺ CD8⁺ T cells after transplantation. Furthermore, neo-expression of HLA-G in the epidermis of patients with clinical GVHD, and a direct correlation of HLA-G expression with the severity of skin GVHD, suggests that up-regulation of HLA-G is involved in the etiology or clinical manifestation of this disease. In an independent study of patients undergoing HCT for hematologic malignancies, high levels of soluble HLA-G proteins within the first month after HCT could be recovered in patients who did not develop acute GVHD; the level of soluble HLA-G proteins correlated with the frequency of T regulatory cells with the CD4⁺ CD25⁺ CD152⁺ phenotype in transplant recipients⁸⁸.

In addition to HLA-E and -G, the *MICA* gene has been an attractive candidate to explain GVHD risks in related and unrelated donor transplantation. A total of 106 unique alleles giving rise to 82 proteins are recognized¹⁷. Although *MICA* shows sequence homology with HLA-A, -B, and -C, it lacks association with $\beta 2$ -microglobulin and does not bind or present peptides. *MICA* is expressed on the epithelium of the gastrointestinal tract (hence

the interest in GVHD) and is induced by cellular stress⁹⁰. The MICA CD94/NKG2D activating receptor is expressed on most $\gamma\delta$ T cells, $\alpha\beta$ T cells, and NK cells⁹¹. Engagement of MICA with NKG2D leads to NK-mediated killing of target cells and CD8-positive $\gamma\delta$ T cell-mediated activation of CTLs⁹²⁻⁹⁶. It is no surprise then that MICA-NKG2D has been implicated in host resistance and susceptibility to infection⁹⁷, tumor surveillance⁹⁸⁻¹⁰⁰, and autoimmunity¹⁰¹⁻¹⁰³. Particular attention has been paid to the rs1051792 variation that gives rise to methionine or valine at residue 129 of the MICA α domain; importantly, this position is associated with lower (valine) or higher (methionine) binding affinity to NKG2D¹⁰⁴ and impacts the strength of NKG2D signaling and co-stimulation of CD8+ T cells^{95,97}.

Early investigation into the HLA-B-HLA-C region of class I uncovered donor-recipient mismatching for a series of markers, which were identified as MICA and MICB, and their potential relevance in HCT outcomes¹⁰⁵. Subsequently, a series of studies have shed light on the importance of donor-recipient MICA mismatching and the Met129Val polymorphism in clinical outcome after related and unrelated donor transplantation^{96,106-110}. The extensive linkage disequilibrium across the MHC favors MICA matching among transplant pairs who are HLA-A, -B, -C, -DRB1, and -DQB1-matched. The clinical significance of MICA mismatching on GVHD risk has been heterogeneous and is likely complicated by a low mismatch rate and population differences. Higher risk of acute GVHD, in particular GVHD of the gastrointestinal tract, has been observed with donor-recipient MICA mismatching in some^{106,109} but not in other studies¹⁰⁷. Recently, a large retrospective analysis of unrelated donor-matched and -mismatched transplants performed in Germany demonstrated higher risks of mortality, lower disease-free survival, and higher rates of acute GVHD with donor-recipient mismatching for Val129Met¹⁰⁸. The presence of 129Met in recipients correlated with better overall survival and lower risk of death due to GVHD; however, homozygous 129Met/Met patients had increased risks⁹⁶. A retrospective study of MICA performed by the CIBMTR found no association of MICA mismatching nor Val129Met on clinical outcome¹¹⁰. The reasons for these heterogeneous results are unclear but may be the result of multifactorial genetic and environmental factors.

Single nucleotide polymorphism mapping

The use of SNPs for fine mapping novel transplantation determinants within the MHC is founded on the concept that tightly linked markers serve as proxies for one another. The use of tagSNPs makes no *a priori* assumptions for the likely disease-causing genes or their associated pathways; for a region that contains the most immune-related genes anywhere in the genome, tagSNPs provide an efficient and robust way to locate novel transplantation determinants. The elucidation of conserved extended HLA haplotypes provided the much-needed reference sequence(s) for designing SNP arrays for disease mapping¹¹¹⁻¹¹³. The availability of NGS methods has permitted the completion of in-depth interrogation of extended haplotypes that are homozygous for the classical HLA alleles, providing unprecedented annotation of coding and non-coding regions of the MHC¹¹⁴. When the classical HLA-A1, -B8, -DR3 and HLA-A2, -B,

-DR15 haplotypes are aligned, extreme levels of sequence conservation over 3 Mb in length are evident¹¹¹. Further appreciation of the nature and organization of genetic variation on extended HLA haplotypes is demonstrated in the analysis of common haplotypes in ethnically diverse populations. In Japan, for example, unrelated individuals show remarkable sequence conservation for the three most common HLA haplotypes, spanning 3.3 Mb in length¹¹⁵.

Demonstration that haplotype-based approaches can facilitate the identification of novel transplantation determinants was shown in a study of HLA-matched unrelated donor-recipient pairs using a long-range phasing method¹¹⁶. The physical linkage of HLA-A, HLA-B, and HLA-DR on the same chromosomal strand was performed to identify matched pairs with the same HLA-A, -B, and -DR haplotypes and matched pairs with different haplotypes. HLA-matched pairs with different haplotypes had a significantly increased risk of grade III-IV acute GVHD, lower relapse, and similar overall survival⁵⁹. These observations suggest that the HLA haplotype can be used as a surrogate marker for GVHD risk and for the identification of specific risk loci. To this end, SNP arrays have been used to query the MHC in matched and mismatched unrelated donor transplants. In HLA-matched transplantation, two SNPs were validated as determinants of survival and acute GVHD¹¹⁷ and a similar strategy is informative for single-locus mismatched unrelated donor transplants¹¹⁸. Collectively, the data thus far point to the presence of MHC resident variation that may confer risks alongside those stemming from HLA mismatching between the donor and the recipient. This information will enhance our understanding of the MHC as a critical region of the genome in transplantation biology and provide potential novel approaches for donor selection and for targeted immunotherapy.

The role for non-major histocompatibility complex loci

Differences between the transplant patient's and donor's HLA class I and II gene products serve as potent antigens that stimulate GVH alloresponses, as described above. HLA class I genes also serve as the cognate ligands for NK cell receptors¹¹⁹. Furthermore, differences in the peptides presented by the patient's HLA class I and II molecules which are recognized by donor T cells as minor histocompatibility antigens represent an important source of variation that contributes to GVHD¹²⁰. For these reasons, the HLA system is a dynamic interface between the innate and adaptive immune systems, each of which has biological implications in HCT.

Human leukocyte antigen ligands for natural killer cells

NK cells do not directly cause GVHD after HLA-matched or HLA-mismatched transplantation. Unlike T cells, which recognize recipient major HLA and minor histocompatibility differences in host leukemia and normal tissues, NK cells recognize target cells that lack class I ligands (missing self; missing ligand), a situation that may arise with viral infection or malignant transformation. Inhibitory KIR receptors interact with their cognate ligands during NK development, which induces tolerance to target cells¹²¹. Target cells that are virally infected or are transformed by malignancy may lose their self-class I ligands; these target cells are recognized by licensed NK cells, leading to target cytotoxicity. In HLA-matched transplantation, patients who lack KIR ligands

(missing ligand) experience lower risk of relapse and improved overall survival¹²², consistent with cytotoxicity of host residual leukemia by unlicensed NK cells. In HLA-mismatched transplantation, wherein the patient lacks KIR ligands that are present in the donor, licensed NK cells can mediate cytotoxicity against the KIR ligand mismatch¹²³. The reduction in relapse in both scenarios is not accompanied by increased GVHD. These unique properties of NK cells are the basis for the development of NK cells in adoptive immunotherapy¹²⁴.

Inhibitory *KIR* genes demonstrate a range of allelic variation and the alleles may have higher or lower degrees of inhibition that add to the diversity of individual immune responses. One example illustrates that features of both the receptor, KIR3DL1, and the ligand, HLA-Bw4, can be associated with different risks of relapse and mortality depending on the strength of inhibition (high or low) and the specific residue 80 sequence polymorphism in Bw4-positive cells¹²⁵. An added layer of polymorphism in the KIR genetic system is the organization of genes into two major haplotype groups defined by the number and nature of genes with inhibitory and activating potential¹²⁶; whereas “A” haplotypes encode more inhibitory than activating genes, “B” haplotypes tend to encode more activating genes than do “A” haplotypes. Haplotype-based analyses of KIR demonstrate the importance of the number and nature of inhibitory and activating genes on A and B haplotypes on transplant outcomes. The presence of at least one B haplotype is associated with improved survival compared to lack of any B haplotype (i.e. only A haplotypes). These data support a role for activating KIRs in transplantation¹²⁷. Among the activating genes that have been studied thus far, the KIR2DS2 receptor and its HLA-C ligands expressing Asn77 and Lys80 (“C2” ligands) are capable of mediating strong anti-leukemic potential¹²⁸. The unique features of activating and inhibitory receptors together with their ligands provide avenues for lowering risk of relapse without an increase of GVHD through KIR-based algorithms applied to donor selection¹²⁹.

Minor histocompatibility antigens

CD8⁺ and CD4⁺ T cells play a role in antigen-mediated recognition leading to GVHD after allogeneic transplantation. By definition, minor histocompatibility antigens are non-self peptides in which one or several polymorphisms within the homologous proteins between a transplant donor and patient may lead to altered binding of peptide to HLA and/or recognition of the HLA-peptide complex by T cells^{130,131}. Due to the diversity of minor histocompatibility antigens that can be presented by HLA, donor T cell-mediated allorecognition of disparities in minor histocompatibility antigens presented by patient target cells may induce GVHD in both HLA-matched and HLA-mismatched transplantation from both related and unrelated donors.

The millions of nucleotide sequence variants within the human genome provide a rich source for potential minor histocompatibility antigens^{132–134}. Variation within autosomal genes and genes

of the Y chromosome contribute minor antigens of importance to transplantation¹³⁵. One of the best-studied minor histocompatibility antigens is the *HMHA1* gene-derived “HA-1” nonamer peptide presented by HLA-A*02:01 allotypes; for this minor antigen, both HLA and T cell receptor binding features contribute to the immunogenicity of HA-1^{136,137}.

Since SNPs represent the most common form of genetic variation accounting for the generation of minor histocompatibility antigens, the availability of SNP arrays to query whole genomes has yielded new insight into the loci that contribute to the pool of clinically relevant minor antigens^{33,47,138}. In a Japanese study of HLA 10/10-matched unrelated donor transplants, autosomal SNPs have been identified that significantly increase the risk of GVHD. The identification of the true causative genes awaits further investigation in independent cohorts.

To predict the extent to which patient mismatching for minor histocompatibility antigens can contribute to GVHD risk, a single-center GWAS analysis compared the degree of genome-wide mismatching of donor anti-host recognition between HLA-matched sibling transplants and HLA-matched unrelated donor transplants³³. On average, 17.3% of unrelated transplants were mismatched for coding SNPs compared to 9.4% of HLA-identical sibling pairs. HLA-matched unrelated donor transplants overall had low GVHD-related outcome risks. The risk was higher among HLA-DP mismatched unrelated donor transplants compared to HLA-matched sibling transplants. These data suggest that GVHD risk after unrelated donor transplantation is conferred in large part by HLA disparity through direct recognition of the mismatched HLA as well as HLA-peptide complexes. Future analysis of larger cohorts will be required to fully examine whether coding SNP variation is a robust proxy for overall degree of minor antigen mismatching and whether genome-wide patient SNP mismatching can contribute to GVHD after unrelated donor transplantation.

Future considerations

The field of HLA continues to push the boundaries of transplantation genetics, from the perspective of basic understanding of the nature and organization of human genetic variation to genes that participate in the immune response. A greater appreciation for the biological implications of non-coding region variation will continue to provide insight into the relationship between the structure and function of MHC resident genes.

Competing interests

The author declares that she has no competing interests.

Grant information

Funding was received from the National Institutes of Health (grant numbers AI069197, CA100019, CA162194, and CA18029).

References



1. Petersdorf EW: **The World Marrow Donor Association: 20 years of international collaboration for the support of unrelated donor and cord blood hematopoietic cell transplantation.** *Bone Marrow Transplant.* 2010; **45**(5): 807–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. **F** Kollman C, Spellman SR, Zhang MJ, *et al.*: **The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.** *Blood.* 2016; **127**(2): 260–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
3. Dausset J, Nenna A: **[Presence of leuko-agglutinin in the serum of a case of chronic agranulocytosis].** *C R Seances Soc Biol Fil.* 1952; **146**(19–20): 1539–41.
[PubMed Abstract](#)
4. van Rood JJ, Eernisse JG, van Leeuwen A: **Leucocyte antibodies in sera from pregnant women.** *Nature.* 1958; **181**(4625): 1735–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Payne R, Tripp M, Weigle J, *et al.*: **A new leukocyte isoantigen system in man.** *Cold Spring Harb Symp Quant Biol.* 1964; **29**: 285–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Bodmer W, Bodmer J, Adler S, *et al.*: **Genetics of “4” and “LA” human leukocyte groups.** *Ann N Y Acad Sci.* 1966; **129**: 473–89.
[Publisher Full Text](#)
7. Kasamon YL, Luznik L, Leffell MS, *et al.*: **Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.** *Biol Blood Marrow Transplant.* 2010; **16**(4): 482–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. **F** McCurdy SR, Fuchs EJ: **Selecting the best haploidentical donor.** *Semin Hematol.* 2016; **53**(4): 246–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
9. **F** Apperley J, Niederwieser D, Huang XJ, *et al.*: **Haploidentical Hematopoietic Stem Cell Transplantation: A Global Overview Comparing Asia, the European Union, and the United States.** *Biol Blood Marrow Transplant.* 2016; **22**(1): 23–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
10. **Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium.** *Nature.* 1999; **401**(6756): 921–3.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. **F** Stewart CA, Horton R, Allcock RJ, *et al.*: **Complete MHC haplotype sequencing for common disease gene mapping.** *Genome Res.* 2004; **14**(6): 1176–87.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
12. Sasazuki T, Inoko H, Morishima S, *et al.*: **Gene Map of the HLA Region, Graves' Disease and Hashimoto Thyroiditis, and Hematopoietic Stem Cell Transplantation.** *Adv Immunol.* 2016; **129**: 175–249.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. **F** Lange V, Böhme I, Hofmann J, *et al.*: **Cost-efficient high-throughput HLA typing by MiSeq amplicon sequencing.** *BMC Genomics.* 2014; **15**: 63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
14. **F** Cereb N, Kim HR, Ryu J, *et al.*: **Advances in DNA sequencing technologies for high resolution HLA typing.** *Hum Immunol.* 2015; **76**(12): 923–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
15. **F** Mayor NP, Robinson J, McWhinnie AJ, *et al.*: **HLA Typing for the Next Generation.** *PLoS One.* 2015; **10**(5): e0127153.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
16. **F** Duke JL, Lind C, Mackiewicz K, *et al.*: **Determining performance characteristics of an NGS-based HLA typing method for clinical applications.** *HLA.* 2016; **87**(3): 141–52.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
17. European Bioinformatics Institute: **IPD-IMGT/HLA Database [Internet].** Hinxton: European Bioinformatics Institute; 2016; [cited 2016 Dec 07].
[Reference Source](#)
18. Horowitz MM: **Uses and growth of hematopoietic cell transplantation.** In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, ed. *Thomas' Hematopoietic Cell Transplantation.* 5th edn. Chichester: John Wiley & Sons, Ltd, 2016; 8–15.
[Publisher Full Text](#)
19. **F** Lee SJ, Klein J, Haagenson M, *et al.*: **High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.** *Blood.* 2007; **110**(13): 4576–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
20. **F** Morishima Y, Kashiwase K, Matsuo K, *et al.*: **Biological significance of HLA locus matching in unrelated donor bone marrow transplantation.** *Blood.* 2015; **125**(7): 1189–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
21. Spellman S, Setterholm M, Maiers M, *et al.*: **Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry.** *Biol Blood Marrow Transplant.* 2008; **14**(9 Suppl): 37–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. **F** Gragert L, Eapen M, Williams E, *et al.*: **HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.** *N Engl J Med.* 2014; **371**(4): 339–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
23. The Allele Frequency Net Database: **Allele, haplotype and genotype frequencies in Worldwide Populations [Internet].** Allelefreqencies.net; 2016; [cited 2016 Dec 013]. [Reference Source](#)
24. National Marrow Donor Program: **NMDP Frequencies [Internet].** Frequency.nmdp.org; 2016; [cited 2016 Dec 013]. [Reference Source](#)
25. **F** Dehn J, Buck K, Maiers M, *et al.*: **8/8 and 10/10 high-resolution match rate for the be the match unrelated donor registry.** *Biol Blood Marrow Transplant.* 2015; **21**(1): 137–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
26. **F** Buck K, Wadsworth K, Setterholm M, *et al.*: **High-Resolution Match Rate of 7/8 and 9/10 or Better for the Be The Match Unrelated Donor Registry.** *Biol Blood Marrow Transplant.* 2016; **22**(4): 759–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | **F1000 Recommendation**
27. Petersdorf EW, Anasetti C, Martin PJ, *et al.*: **Limits of HLA mismatching in unrelated hematopoietic cell transplantation.** *Blood.* 2004; **104**(9): 2976–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Bjorkman PJ, Parham P: **Structure, function, and diversity of class I major histocompatibility complex molecules.** *Annu Rev Biochem.* 1990; **59**: 253–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Salter RD, Benjamin RJ, Wesley PK, *et al.*: **A binding site for the T-cell co-receptor CD8 on the alpha₁ domain of HLA-A2.** *Nature.* 1990; **345**(6270): 41–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Petersdorf EW, Gooley T, Malkki M, *et al.*: **The biological significance of HLA-DP gene variation in haematopoietic cell transplantation.** *Br J Haematol.* 2001; **112**(4): 988–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Ogawa S, Matsubara A, Onizuka M, *et al.*: **Exploration of the genetic basis of GVHD by genetic association studies.** *Biol Blood Marrow Transplant.* 2009; **15**(1 Suppl): 39–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Shaw BE, Mayor NP, Russell NH, *et al.*: **Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles.** *Leukemia.* 2010; **24**(1): 58–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. **F** Martin PJ, Levine DM, Storer BE, *et al.*: **Genome-wide minor histocompatibility matching as related to the risk of graft-versus-host disease.** *Blood.* 2017; **129**(6): 791–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
34. Anasetti C, Hansen JA: **Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors.** *Transfus Sci.* 1994; **15**(3): 221–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Petersdorf EW, Hansen JA, Martin PJ, *et al.*: **Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation.** *N Engl J Med.* 2001; **345**(25): 1794–800.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Fernández-Viña MA, Klein JP, Haagenson M, *et al.*: **Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.** *Blood.* 2013; **121**(22): 4603–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Ferrara GB, Bacigalupo A, Lamparelli T, *et al.*: **Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain.** *Blood.* 2001; **98**(10): 3150–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Fleischhauer K, Kernan NA, O'Reilly RJ, *et al.*: **Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44.** *N Engl J Med.* 1990; **323**(26): 1818–22.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Kawase T, Morishima Y, Matsuo K, *et al.*: **High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism.** *Blood.* 2007; **110**(7): 2235–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Pidala J, Wang T, Haagenson M, *et al.*: **Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.** *Blood.* 2013; **122**(22): 3651–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

41. Fleischhauer K, Zino E, Mazzi B, *et al.*: **Peripheral blood stem cell allograft rejection mediated by CD4⁺ T lymphocytes recognizing a single mismatch at HLA-DP beta 1*0901.** *Blood.* 2001; **98**: 1122–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Zino E, Frumento G, Markt S, *et al.*: **A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation.** *Blood.* 2004; **103**(4): 1417–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Crocchiolo R, Zino E, Vago L, *et al.*: **Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation.** *Blood.* 2009; **114**(7): 1437–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. **F** Fleischhauer K, Shaw BE, Gooley T, *et al.*: **Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study.** *Lancet Oncol.* 2012; **13**(4): 366–74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
45. Pidalá J, Lee SJ, Ahn KW, *et al.*: **Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.** *Blood.* 2014; **124**(16): 2596–606.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. **F** Crivello P, Heinold A, Rebmann V, *et al.*: **Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT.** *Blood.* 2016; **128**(1): 120–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
47. **F** Inamoto Y, Martin PJ, Flowers ME, *et al.*: **Genetic risk factors for sclerotic graft-versus-host disease.** *Blood.* 2016; **128**(11): 1516–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
48. **F** Apps R, Qi Y, Carlson JM, *et al.*: **Influence of HLA-C expression level on HIV control.** *Science.* 2013; **340**(6128): 87–91.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
49. Thomas R, Thio CL, Apps R, *et al.*: **A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection.** *J Virol.* 2012; **86**(12): 6979–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
50. Petersdorf EW, Gooley TA, Malkki M, *et al.*: **HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation.** *Blood.* 2014; **124**(26): 3996–4003.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. **F** Petersdorf EW, Malkki M, O'Huigin C, *et al.*: **High HLA-DP Expression and Graft-versus-Host Disease.** *N Engl J Med.* 2015; **373**(7): 599–609.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
52. Weiden PL, Flournoy N, Thomas ED, *et al.*: **Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.** *N Engl J Med.* 1979; **300**(19): 1068–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. Horowitz MM, Gale RP, Sondel PM, *et al.*: **Graft-versus-leukemia reactions after bone marrow transplantation.** *Blood.* 1990; **75**(3): 555–62.
[PubMed Abstract](#)
54. Kolb HJ, Socié G, Duell T, *et al.*: **Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group.** *Ann Intern Med.* 1999; **131**(10): 738–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Gratwohl A, Brand R, Apperley J, *et al.*: **Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.** *Blood.* 2002; **100**(12): 3877–86.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. **F** Herr W, Eichinger Y, Beshay J, *et al.*: **HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.** *Leukemia.* 2017; **31**(2): 434–45.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
57. Chien JW, Zhang XC, Fan W, *et al.*: **Evaluation of published single nucleotide polymorphisms associated with acute GVHD.** *Blood.* 2012; **119**(22): 5311–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
58. Petersdorf EW: **The major histocompatibility complex: a model for understanding graft-versus-host disease.** *Blood.* 2013; **122**(11): 1863–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
59. **F** Petersdorf EW, Malkki M, Gooley TA, *et al.*: **MHC haplotype matching for unrelated hematopoietic cell transplantation.** *PLoS Med.* 2007; **4**(1): e8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
60. Tamouza R, Busson M, Rocha V, *et al.*: **Homozygous status for HLA-E*0103 confers protection from acute graft-versus-host disease and transplant-related mortality in HLA-matched sibling hematopoietic stem cell transplantation.** *Transplantation.* 2006; **82**(11): 1436–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
61. Ludajic K, Rosenmayr A, Fae I, *et al.*: **Association of HLA-E polymorphism with the outcome of hematopoietic stem-cell transplantation with unrelated donors.** *Transplantation.* 2009; **88**(10): 1227–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. Hosseini E, Schwarzer AP, Ghasemzadeh M: **The impact of HLA-E polymorphisms in graft-versus-host disease following HLA-E matched allogeneic hematopoietic stem cell transplantation.** *Iran J Allergy Asthma Immunol.* 2012; **11**(1): 15–21.
[PubMed Abstract](#)
63. **F** Harkensee C, Oka A, Onizuka M, *et al.*: **Single nucleotide polymorphisms and outcome risk in unrelated mismatched hematopoietic stem cell transplantation: an exploration study.** *Blood.* 2012; **119**(26): 6365–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
64. Furst D, Bindja J, Arnold R, *et al.*: **HLA-E polymorphisms in hematopoietic stem cell transplantation.** *Tissue Antigens.* 2012; **79**(4): 287–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Geraghty DE, Pei J, Lipsky B, *et al.*: **Cloning and physical mapping of the HLA class I region spanning the HLA-E-to-HLA-F interval by using yeast artificial chromosomes.** *Proc Natl Acad Sci U S A.* 1992; **89**(7): 2669–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
66. **F** Carosella ED, Gregori S, Rouas-Freiss N, *et al.*: **The role of HLA-G in immunity and hematopoiesis.** *Cell Mol Life Sci.* 2011; **68**(3): 353–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
67. Carosella ED, Moreau P, Le Maoult J, *et al.*: **HLA-G molecules: from maternal-fetal tolerance to tissue acceptance.** *Adv Immunol.* 2003; **81**: 199–252.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. **F** Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, *et al.*: **HLA-G: An Immune Checkpoint Molecule.** *Adv Immunol.* 2015; **127**: 33–144.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
69. Hviid TV, Hylenius S, Rorbye C, *et al.*: **HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels.** *Immunogenetics.* 2003; **55**(2): 63–79.
[PubMed Abstract](#) | [Publisher Full Text](#)
70. Tan Z, Shon AM, Ober C: **Evidence of balancing selection at the HLA-G promoter region.** *Hum Mol Genet.* 2005; **14**(23): 3619–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Castelli EC, Mendes-Junior CT, Deghaide NH, *et al.*: **The genetic structure of 3'untranslated region of the HLA-G gene: polymorphisms and haplotypes.** *Genes Immun.* 2010; **11**(2): 134–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Rizzo R, Hviid TV, Govoni M, *et al.*: **HLA-G genotype and HLA-G expression in systemic lupus erythematosus: HLA-G as a putative susceptibility gene in systemic lupus erythematosus.** *Tissue Antigens.* 2008; **71**(6): 520–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Veit TD, Vianna P, Scheibel I, *et al.*: **Association of the HLA-G 14-bp insertion/deletion polymorphism with juvenile idiopathic arthritis and rheumatoid arthritis.** *Tissue Antigens.* 2008; **71**(5): 440–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
74. Veit TD, Cordero EA, Mucenic T, *et al.*: **Association of the HLA-G 14 bp polymorphism with systemic lupus erythematosus.** *Lupus.* 2009; **18**(5): 424–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
75. Rousseau P, Le Discorde M, Mouillot G, *et al.*: **The 14 bp deletion-insertion polymorphism in the 3' UT region of the HLA-G gene influences HLA-G mRNA stability.** *Hum Immunol.* 2003; **64**(11): 1005–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
76. Chen XY, Yan WH, Lin A, *et al.*: **The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma.** *Tissue Antigens.* 2008; **72**(4): 335–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
77. Rouas-Freiss N, Marchal RE, Kirszenbaum M, *et al.*: **The alpha₁ domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors?** *Proc Natl Acad Sci U S A.* 1997; **94**(10): 5249–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
78. LeMaoult J, Krawice-Radanne I, Dausset J, *et al.*: **HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4⁺ T cells.** *Proc Natl Acad Sci U S A.* 2004; **101**(18): 7064–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
79. McIntire RH, Hunt JS: **Antigen presenting cells and HLA-G—a review.** *Placenta.* 2005; **26**(Suppl A): S104–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
80. Tripathi P, Abbas A, Naik S, *et al.*: **Role of 14-bp deletion in the HLA-G gene in the maintenance of pregnancy.** *Tissue Antigens.* 2004; **64**(6): 706–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
81. Larsen MH, Hviid TV: **Human leukocyte antigen-G polymorphism in relation to expression, function, and disease.** *Hum Immunol.* 2009; **70**(12): 1026–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
82. La Nasa G, Littera R, Locatelli F, *et al.*: **The human leucocyte antigen-G 14-basepair polymorphism correlates with graft-versus-host disease in unrelated bone marrow transplantation for thalassaemia.** *Br J Haematol.* 2007; **139**(2): 284–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
83. Boukouaci W, Busson M, Fortier C, *et al.*: **Association of HLA-G low expressor genotype with severe acute graft-versus-host disease after sibling bone marrow transplantation.** *Front Immunol.* 2011; **2**: 74.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
84. Chiusolo P, Bellesi S, Piccirillo N, *et al.*: **The role of HLA-G 14-bp polymorphism in allo-HSCT after short-term course MTX for GvHD prophylaxis.** *Bone Marrow*

- Transplant.* 2012; **47**(1): 120–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
85. Sizzano F, Testi M, Zito L, *et al.*: **Genotypes and haplotypes in the 3' untranslated region of the HLA-G gene and their association with clinical outcome of hematopoietic stem cell transplantation for beta-thalassemia.** *Tissue Antigens.* 2012; **79**(5): 326–32.
[PubMed Abstract](#) | [Publisher Full Text](#)
86. Waterhouse M, Duque-Afonso J, Wäscher R, *et al.*: **Soluble HLA-G molecules and HLA-G 14-base pair polymorphism after allogeneic hematopoietic cell transplantation.** *Transplant Proc.* 2013; **45**(1): 397–401.
[PubMed Abstract](#) | [Publisher Full Text](#)
87. Lazana I, Zoudiari A, Kokkinou D, *et al.*: **Identification of a novel HLA-G* regulatory population in blood: expansion after allogeneic transplantation and *de novo* HLA-G expression at graft-versus-host disease sites.** *Haematologica.* 2012; **97**(9): 1338–47.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
88. Le Maux A, Noël G, Birebent B, *et al.*: **Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation: a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells.** *Clin Exp Immunol.* 2008; **152**(1): 50–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Liu H, Chen Y, Xuan L, *et al.*: **Soluble human leukocyte antigen G molecule expression in allogeneic hematopoietic stem cell transplantation: good predictor of acute graft-versus-host disease.** *Acta Haematol.* 2013; **130**(3): 160–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Groh V, Bahram S, Bauer S, *et al.*: **Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium.** *Proc Natl Acad Sci U S A.* 1996; **93**(22): 12445–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
91. Tieng V, Le Bouguéne C, du Merle L, *et al.*: **Binding of *Escherichia coli* adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA.** *Proc Natl Acad Sci U S A.* 2002; **99**(5): 2977–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
92. Bahram S, Bresnahan M, Geraghty DE, *et al.*: **A second lineage of mammalian major histocompatibility complex class I genes.** *Proc Natl Acad Sci U S A.* 1994; **91**(14): 6259–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
93. Bauer S, Groh V, Wu J, *et al.*: **Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.** *Science.* 1999; **285**(5428): 727–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
94. Groh V, Rhinehart R, Randolph-Habecker J, *et al.*: **Costimulation of CD8 α alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells.** *Nat Immunol.* 2001; **2**(3): 255–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
95. **F** Billadeau DD, Upshaw JL, Schoon RA, *et al.*: **NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.** *Nat Immunol.* 2003; **4**(6): 557–64.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
96. **F** Isernhagen A, Malzahn D, Viktorova E, *et al.*: **The MICA-129 dimorphism affects NKG2D signaling and outcome of hematopoietic stem cell transplantation.** *EMBO Mol Med.* 2015; **7**(11): 1480–502.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
97. Wesselkamper SC, Eppert BL, Motz GT, *et al.*: **NKG2D is critical for NK cell activation in host defense against *Pseudomonas aeruginosa* respiratory infection.** *J Immunol.* 2008; **181**(8): 5481–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. **F** Guerra N, Tan YX, Joncker NT, *et al.*: **NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.** *Immunity.* 2008; **28**(4): 571–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
99. Douik H, Ben Chaaben A, Attia Romdhane N, *et al.*: **Association of MICA-129 polymorphism with nasopharyngeal cancer risk in a Tunisian population.** *Hum Immunol.* 2009; **70**(1): 45–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. **F** Campillo JA, López-Hernández R, Martínez-Banaclocha H, *et al.*: **MHC class I chain-related gene a diversity in patients with cutaneous malignant melanoma from southeastern Spain.** *Dis Markers.* 2015; **2015**: 831864.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
101. López-Hernández R, Valdés M, Lucas D, *et al.*: **Association analysis of MICA gene polymorphism and MICA-129 dimorphism with inflammatory bowel disease susceptibility in a Spanish population.** *Hum Immunol.* 2010; **71**(5): 512–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
102. Yoshida K, Komai K, Shiozawa K, *et al.*: **Role of the MICA polymorphism in systemic lupus erythematosus.** *Arthritis Rheum.* 2011; **63**(10): 3058–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. Raache R, Belanteur K, Amroun H, *et al.*: **Association of major histocompatibility complex class 1 chain-related gene a dimorphism with type 1 diabetes and latent autoimmune diabetes in adults in the Algerian population.** *Clin Vaccine Immunol.* 2012; **19**(4): 557–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Steinle A, Li P, Morris DL, *et al.*: **Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.** *Immunogenetics.* 2001; **53**(4): 279–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. Kitcharoen K, Witt CS, Romphruk AV, *et al.*: **MICA, MICB, and MHC beta block matching in bone marrow transplantation: relevance to transplantation outcome.** *Hum Immunol.* 2006; **67**(3): 238–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
106. Parmar S, Del Lima M, Zou Y, *et al.*: **Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease.** *Blood.* 2009; **114**(14): 2884–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Anderson E, Grzywacz B, Wang H, *et al.*: **Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation.** *Blood.* 2009; **114**(21): 4753–4; author reply 4754–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
108. **F** Fuerst D, Neuchel C, Niederwieser D, *et al.*: **Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.** *Blood.* 2016; **128**(26): 3169–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
109. **F** Carapito R, Jung N, Kwemou M, *et al.*: **Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.** *Blood.* 2016; **128**(15): 1979–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
110. **F** Askar M, Sobechs R, Wang T, *et al.*: **MHC Class I Chain-Related Gene A (MICA) Donor-Recipient Mismatches and MICA-129 Polymorphism in Unrelated Donor Hematopoietic Cell Transplantations Has No Impact on Outcomes in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome: A Center for International Blood and Marrow Transplant Research Study.** *Biol Blood Marrow Transplant.* 2017; **23**(3): 436–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
111. de Bakker PI, McVean G, Sabeti PC, *et al.*: **A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC.** *Nat Genet.* 2006; **38**(10): 1166–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
112. Baschal EE, Aly TA, Jasinski JM, *et al.*: **Defining multiple common “completely” conserved major histocompatibility complex SNP haplotypes.** *Clin Immunol.* 2009; **132**(2): 203–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. UCL Cancer Institute: **Medical Genomics.** Sanger.ac.uk; 2017, [cited 2017 Feb 10]. [Reference Source](#)
114. Norman PJ, Norberg SJ, Nemat-Gorgani N, *et al.*: **Very long haplotype tracts characterized at high resolution from HLA homozygous cell lines.** *Immunogenetics.* 2015; **67**(9): 479–85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Morishima S, Ogawa S, Matsubara A, *et al.*: **Impact of highly conserved HLA haplotype on acute graft-versus-host disease.** *Blood.* 2010; **115**(23): 4664–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
116. **F** Guo Z, Hood L, Malkki M, *et al.*: **Long-range multilocus haplotype phasing of the MHC.** *Proc Natl Acad Sci U S A.* 2006; **103**(18): 6964–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
117. Petersdorf EW, Malkki M, Gooley TA, *et al.*: **MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation.** *Sci Transl Med.* 2012; **4**(144): 144ra101.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
118. Petersdorf EW, Malkki M, Horowitz MM, *et al.*: **Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.** *Blood.* 2013; **121**(10): 1896–905.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
119. Parham P, Moffett A: **Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution.** *Nat Rev Immunol.* 2013; **13**(2): 133–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Bleakley M, Riddell SR: **Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.** *Immunol Cell Biol.* 2011; **89**(3): 396–407.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
121. Storkus WJ, Alexander J, Payne JA, *et al.*: **Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.** *Proc Natl Acad Sci U S A.* 1989; **86**(7): 2361–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
122. Giebel S, Locatelli F, Lamparelli T, *et al.*: **Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.** *Blood.* 2003; **102**(3): 814–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
123. **F** Ruggeri L, Capanni M, Urbani E, *et al.*: **Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.** *Science.* 2002; **295**(5562): 2097–100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
124. Miller JS, Soignier Y, Panoskaltis-Mortari A, *et al.*: **Successful adoptive transfer and *in vivo* expansion of human haploidentical NK cells in patients with cancer.** *Blood.* 2005; **105**(8): 3051–7.
[PubMed Abstract](#) | [Publisher Full Text](#)

125. Boudreau J, Giglio F, Gooley T, *et al.*: **KIR3DL1/HLA-B subtypes govern AML relapse after hematopoietic cell transplantation.** *J Clin Oncol.* 2017; In Press.
[PubMed Abstract](#) | [Publisher Full Text](#)
126. Carrington M, Martin MP: **The impact of variation at the KIR gene cluster on human disease.** *Curr Top Microbiol Immunol.* 2006; **298**: 225–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
127. Cooley S, Trachtenberg E, Bergemann TL, *et al.*: **Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.** *Blood.* 2009; **113**(3): 726–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
128. Venstrom JM, Pittari G, Gooley TA, *et al.*: **HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.** *N Engl J Med.* 2012; **367**(9): 805–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
129. **F** Heidenreich S, Kröger N: **Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.** *Front Immunol.* 2017; **8**: 41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
130. Korngold R, Sprent J: **Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow.** *J Exp Med.* 1978; **148**(6): 1687–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
131. Wallny HJ, Rammensee HG: **Identification of classical minor histocompatibility antigen as cell-derived peptide.** *Nature.* 1990; **343**(6255): 275–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
132. **F** International HapMap Consortium: **A haplotype map of the human genome.** *Nature.* 2005; **437**(7063): 1299–320.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
133. Roopenian D, Choi EY, Brown A: **The immunogenomics of minor histocompatibility antigens.** *Immunol Rev.* 2002; **190**(1): 86–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
134. **F** Griffioen M, van Bergen CA, *et al.*: **Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets.** *Front Immunol.* 2016; **7**: 100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
135. **F** Popli R, Sahaf B, Nakasone H, *et al.*: **Clinical impact of H-Y alloimmunity.** *Immunol Res.* 2014; **58**(2–3): 249–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
136. Goulmy E: **Human minor histocompatibility antigens.** *Curr Opin Immunol.* 1996; **8**(1): 75–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
137. den Haan JM, Meadows LM, Wang W, *et al.*: **The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.** *Science.* 1998; **279**(5353): 1054–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
138. **F** Sato-Otsubo A, Nannya Y, Kashiwase K, *et al.*: **Genome-wide surveillance of mismatched alleles for graft-versus-host disease in stem cell transplantation.** *Blood.* 2015; **126**(25): 2752–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:  

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Dietrich Beelen**

Universitätsklinikum Essen, Essen, Germany

Competing Interests: No competing interests were disclosed.

2. **Richard Champlin**

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research